

(An ISO 3297: 2007 Certified Organization)

Vol. 3, Issue 1, January 2014

INFRARED AND THERMAL INTERPRETATIONS OF EUROPIUM (III) NORFLOXACIN COMPLEXES

M.M. AL Majthoub

Associate Professor, Department of Chemistry, Faculty of Science, Taif University, 888 Taif, Kingdom Saudi Arabia

Abstract: Norfloxacin Eu(III) complex was synthesized with chemical formula $[Eu(NFX)_3].6H_2O$. The NFX acts as deprotonated bidentate ligand through the oxygen atom of carbonyl group and the oxygen atom of carboxylic group. Elemental analysis, FT–IR spectral, electrical conductivity, thermal analysis (TG/DTA) studies have been used to characterize the mentioned isolated complex.

Keywords: Norfloxacin, Europium, Conductivity, Infrared, Thermal.

I. INTRODUCTION

Metalloantibiotics can interact with several different kinds of biomolecules, including DNA, RNA, proteins, receptors, and lipids, rendering their unique and specific bioactivities. Antibiotics that interact with metal ions constituted a class of drugs which has been widely used in medicine both for human beings and animals [1, 2]. Many drugs possess modified pharmacological and toxicological properties when administered in the form of metallic complexes. Probably the most widely studied cation in this respect is Cu(II), for which a host of low-molecular-weight Cu(II) complexes have been proved beneficial against several diseases such as tuberculosis, rheumatoid arthritis, gastric ulcers, and cancers [3, 4]. Norfloxacin is considered the best of the third generation quinolone family. There are several reports regarding the synthesis and crystal structure of metal complexes with quinolone derivatives [5, 6]. Quinolone antibiotics could participate in the formation of complexes in a number of ways [7, 8]. When in acidic media, quinolones are usually singly and/or doubly protonated making them unable to coordinate to the metal cations and, in such cases, only electrostatic interaction are observed between the drug and the metal ions [9]. There are several metal–NFX complexes and their biological activities studies have been reported [23-28]. This paper was discussed the interaction behavior between the europium(III) and NFX antibiotic ligand using infrared and thermal tools.

II. EXPERIMENTAL

The EuCl₃.6H₂O, NFX (Fig. 1) and methanol solvent were obtained from Aldrich Company. All chemicals used in this study were of analytically reagent grade and used without further purification. The 3 mmol of NFX suspended in 50 mL of methanol was mixed with another solution containing 1 mmol of the EuCl₃.6H₂O in 25 mL distilled water. The reaction mixture was then basified by adding ammonia solution (1 M) and was refluxed at ~ 80 °C for about 6 h. The product obtained as a precipitate was collected by filtration and washed with a mixture of methanol/water (50/50; v/v). The product thus obtained was dried (80 °C) under *vacuum* over anhydrous calcium chloride. Elemental analyses of carbon, hydrogen and nitrogen elements were analyzed by a Perkin-Elmer CHN 2400 elemental analyzer. The europium metal content was calculated gravimetrically by converting the europium-NFX complex to its corresponding Eu₂O₃ oxide. The molar conductivity of freshly prepared 1.0×10^{-3} mol/cm³ dimethylsulfoxide solutions were measured for the soluble complex using Jenway 4010 conductivity meter. The infrared spectra, as KBr discs, were recorded on a Bruker FT-IR Spectrophotometer (4000–400 cm⁻¹). The thermal study was carried out on a Shimadzu thermogravimetric analyzer at a heating rate of 10 °C min⁻¹ under nitrogen till 800 °C.



(An ISO 3297: 2007 Certified Organization)

Vol. 3, Issue 1, January 2014



Fig. 1: The structural formula of NFX antibiotic drug

III. RESULTS AND DISUSSION

The europium-NFX complex with formula $[Eu(NFX)_3].6H_2O$ was assigned under the interaction between Eu(III) chlorides and NFX drug with 1:3 molar ratio. This resulted complex was stable solid at room temperature. Testing for chloride ions held as follows; the solid complex was acidified by adding few drops of concentrated nitric acid. The nitric acid reacts with, and removes, other ions that might also give a confusing precipitate with silver nitrate. The basis of the test is that a solution containing chloride ions changes immediately into a whitish solution when silver nitrate solution is added (0.1 mol/L). If these chloride ions are not present, the solution remains clear and transparent. The molar conductance of the isolated complex indicated that this complex was non-electrolytes [10] which agreed with the elemental analysis data and the absence of chloride ions. Elemental analysis data of the white Eu(III)–NFX complex: Calc. %C:47.45; %H: 5.23; %N: 10.38; %Eu: 12.51, Found. %C: 45.95; %H: 5.21; %N: 9.86; %Eu: 12.37.

The infrared spectrum of the prepared Eu(III)-NFX complex has been represented in Fig. 2. The NFX ligand showed strong broad band near at 3400 cm⁻¹. This band could be assigned to the stretching vibration of the v(N-H)group. This band existed in the spectrum of the Eu(III) complex that indicate the non-participation of this group in the coordination process with metal ions [11]. The free NFX ligand has a two strong bands located at 1620 and 1727 cm⁻¹ which assigned to the stretching vibration of the carboxylic v(COOH) and the carbonyl v(CO) groups [12]. Insight into the spectrum of NFX, it was found that the absence of the vCOOH stretching vibration, explains strongly the deprotonation of NFX ligand [11]. In the literature survey [12] a study which deals with the location of both asymmetric (1585 cm⁻¹) and symmetric (1380 cm⁻¹) stretching depending upon the deprotonation of carboxylate group. The main infrared spectral bands detectable for the NFX ligand in the Eu(III)-NFX complex confirm the deprotonation situation for the Eu(III)-NFX complex. In the chelation process, the carbonyl v(CO) group was disappeared and the v(COOH) stretching vibration in NFX ligand appeared at (1617 and 1616) cm^{-1} and (1335 and 1383) cm^{-1} due to the asymmetric and symmetric stretching vibration of the ligated COO⁻ group, respectively [11, 12]. The $\Delta v = (v_{asym})$ $COO^{-} - v_{sym} COO^{-}$) in case of Eu(III) complex was observed at 238 cm⁻¹, which suggested a uni-dentate interaction of the carboxylate group toward the central metal ions. The other reason, which confirms the place of coordination is that the disappeared of carbonyl group v(C=O) which presence at 1727 cm⁻¹ for the free NFX ligand. The new bands were existed in Eu(III)-NFX complex at 553, 523, 506 and 474 cm⁻¹ assigned to M-O stretching vibration motion [45, 46] of Eu(III) O-carboxylate and Eu(III) O-carbonyl groups. The uncoordinated water molecules were observed at the ~ 3400 cm^{-1} . The suggested chelation of NFX ligand toward Eu(III) metal ion can be illustrated in Fig. 3.





(An ISO 3297: 2007 Certified Organization)

Vol. 3, Issue 1, January 2014







(An ISO 3297: 2007 Certified Organization)

Vol. 3, Issue 1, January 2014



Fig. 3: Suggestion structure of [Eu(NFX)₃].6H₂O complex

Figure 4 show the TG/DTG curves of $[Eu(NFXr)_3].6H_2O$ under nitrogen atmosphere. From this Figure, the following results can be discussed. The TG/DTG curves of the Eu(III)-NFX hydrated complexes show four cconsecutives and successive decomposition steps (DTG_{max} = 141, 251, 336 and 603 °C) with total weight loss 85.89%, it's so difficult to be separated. Logically the first step responsible to the dehydration process and the others are assigned to the decomposition process for the NFX chelating ligands. The processes of dehydration and decomposition of NFX ligand are accompanied by endothermic peaks. The final residue of decomposition of the $[Eu(NFXr)_3].6H_2O$ complex is europium(III) oxide with percentage 14.11%. The result of $\frac{1}{2}Eu_2O_3$ residue was agreed with that of calculated percentage 14.48%. The three terminal of ethyl groups and fluorine atoms of the three NFX moieties are the early groups which were loosed in the form of ethylene and hydrogen fluoride molecules, respectively. The Eu₂O₃ oxide was stable in the temperature range 710–800 °C.



(An ISO 3297: 2007 Certified Organization)

Vol. 3, Issue 1, January 2014





REFERENCES

- [1] A. Zaki, E.C. Schreiber, I. Weliky, J.R. Knill, J.A. Hubsher, J. Clin. Pharmacol., 14 (1974) 118.
- [2] J. Klastersky, D. Daneau, D. Weerts, Chemotherapy 18 (1973) 191.
- [3] D.H. Brown, W.E. Smith, J.W. Teape, A.J. Lewis, J. Med. Chem., 23 (1980) 729.
- [4] M. Ruiz, L. Perelló, R. Ortiz, A. Castiñeiras, C. Maichle-Mössmer, E. Cantón, J. Inorg. Biochem., 59 (1995) 801.
- [5] P. Yang, J.B. Li, Y.N. Tian, K.B. Yu, Chin. Chem. Letts., 10 (1999) 879.
- [6] G. Wu, G. Wang, X. Fu, L. Zhu, Molecules 8(2) (2003) 287.
- [7] Z-F. Chen, R-G. Xiong, J-L. Zuo, Z. Guo, X-Z. You, H-K. Fun, J. Chem. Soc. Dalton Trans (2000) 4013.
- [8] J. Al-Mustafa, Acta Chim. Slov., 49 (2002) 457.
- [9] M. Ruíz, L. Perelló, J. Server-Carrió, R. Ortiz, S. García-Granda, M.R. Díaz, E. Cantón, J. Inorg. Biochem., 69 (1998) 231.
- [10] W.J. Geary, Coord. Chem. Rev., 7 (1971) 81.
- [11] I. Turel, L. Golic, O.L.R. Ramirez, Acta Chem. Slov., 46(2) (1999) 203.
 - I. Turel, I. Leban, N. Bukovec, J. Inorg. Biochem., 66 (1997) 241.